Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.12 | N/A | +90.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.12 | N/A | +90.48% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains optimistic about the company's future prospects. They emphasized the importance of their ongoing initiatives.
Management highlighted the strong performance in EPS despite not providing revenue figures.
They expressed confidence in their ongoing projects and partnerships.
Ligand Pharmaceuticals reported a significant EPS beat, which is a positive sign for the company's profitability. However, the stock fell by 5.76%, likely due to the lack of revenue information and guidance, leaving investors uncertain about future performance. The market reaction suggests that investors were looking for more comprehensive data to assess the company's trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Oct 28, 2013